期刊
EMBO JOURNAL
卷 34, 期 4, 页码 475-490出版社
WILEY
DOI: 10.15252/embj.201489425
关键词
EGFR; LAPTM4B; PIPKI gamma i5; PtdIns(4,5) P-2
资金
- National Institute of Health [CA104708, GM057549]
- Howard Hughes Medical Institute International Student Research Fellowship
- American Heart Association Scientist Development Grant [12SDG11950022]
- American Heart Association Postdoctoral Fellowship [10POST4290052]
- Hilldale Undergraduate/Faculty Research Fellowship
Lysosomal degradation is essential for the termination of EGF-stimulated EGF receptor (EGFR) signaling. This requires EGFR sorting to the intraluminal vesicles (ILVs) of multi-vesicular endosomes (MVEs). Cytosolic proteins including the ESCRT machineries are key regulators of EGFR intraluminal sorting, but roles for endosomal transmembrane proteins in receptor sorting are poorly defined. Here, we show that LAPTM4B, an endosomal transmembrane oncoprotein, inhibits EGF-induced EGFR intraluminal sorting and lysosomal degradation, leading to enhanced and prolonged EGFR signaling. LAPTM4B blocks EGFR sorting by promoting ubiquitination of Hrs (an ESCRT-0 subunit), which inhibits the Hrs association with ubiquitinated EGFR. This is counteracted by the endosomal PIP kinase, PIPKI gamma i5, which directly binds LAPTM4B and neutralizes the inhibitory function of LAPTM4B in EGFR sorting by generating PtdIns(4,5)P-2 and recruiting SNX5. PtdIns(4,5)P-2 and SNX5 function together to protect Hrs from ubiquitination, thereby promoting EGFR intraluminal sorting. These results reveal an essential layer of EGFR trafficking regulated by LAPTM4B, PtdIns(4,5)P-2 signaling, and the ESCRT complex and define a mechanism by which the oncoprotein LAPTM4B can transform cells and promote tumor progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据